Skip to main content
. Author manuscript; available in PMC: 2018 Mar 14.
Published in final edited form as: Biochemistry. 2017 Mar 3;56(10):1529–1535. doi: 10.1021/acs.biochem.6b01125

Figure 1.

Figure 1

Chemical structures of chloroeremomycin (left), [19F]oritavancin (center), and des-N-methylleucyl-4-(4-fluorophenyl)benzyl-chloroeremomycin (desleucyl-[19F]oritavancin) (right). The terminal leucyl residue of the aglycon core of [19F]oritavancin is highlighted.